Amgen NASDAQ: AMGN pharmaceutical company just announced positive performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial.

Trial reached primary endpoint of Reducing new vertebral fractures and secondary endpoints of reducing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation was excited." I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the first fully human monoclonal antibody in late stage clinical development that particularly targets RANK Ligand, an important regulator of osteoclasts the cells that break down bone). Denosumab is being investigated for its potential to inhibit every stage of osteoclast activity by a targeted mechanism. Denosumab is being researched in a range of bone loss conditions including postmenopausal osteoporosis, rheumatoid arthritis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its ability to defer bone metastases and stop and treat bone destruction across many stages of cancer.

Often referred to as the "silent epidemic", osteoporosis is a world wide problem illness that is increasing in dominance as the world population both increases and ages. WHO, The World Health Organization has just identified osteoporosis as a significant health issue along with other major non-communicable diseases. We are dependent on the pharmaceutical companies to help combat this terrible disease.

Amgen states that the economic burden of osteoporosis is referred to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Pharmacist-clinical have been researching prescriptions drugs to help patient that have serious side effects. These products are developed almost at the same time as the medications that assist in the treatment of the primary illness. The fact that data is available to help anticipate the potential side effects and interactions drugs have with one another is awesome.

These medicines are prescribed to prevent and treat osteoporosis. A few prescriptions slow the rate of bone loss or increase bone thickness. Even small amounts of new bone growth may diminish the danger of breaking bones. It is essential that you take vitamin D and calcium, eat well and exercise when you take osteoporosis prescriptions.

prescription drug